STOCK TITAN

[144] DexCom, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

DexCom (DXCM) Form 144 notice reports a proposed sale of 2,750 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $220,797.50 and approximately 392,155,265 shares outstanding. The shares were acquired as vested RSUs on 05/19/2022 and payment was recorded the same day. The filer notes an approximate sale date of 08/15/2025. The filing also discloses two prior sales by the same account: 2,750 shares on 06/16/2025 for $228,604.75 and 2,750 shares on 07/15/2025 for $234,216.67. The notice includes standard Rule 144 representations but contains no entered dates or signature data in the remarks section.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Insider plans to sell 2,750 vested RSU shares via UBS; prior recent sales of identical amounts were disclosed.

The filing documents a routine Rule 144 sale of 2,750 common shares through UBS Financial Services with an indicated sale date of 08/15/2025. Acquisition details show these shares were vested RSUs acquired and paid for on 05/19/2022. The filer also reported two recent sales in June and July 2025, each of 2,750 shares, with gross proceeds disclosed. From a market-impact perspective, the absolute size is small relative to the reported outstanding shares, and the disclosure follows required Rule 144 reporting conventions. The absence of completed entries in the remarks/signature area should be confirmed as an administrative omission.

TL;DR: Filing appears procedurally standard but includes missing entries in the remarks/signature fields that warrant attention.

The Form 144 provides the necessary transaction tables: issuer, broker, class, amount, market value, acquisition source

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Dexcom Inc

NASDAQ:DXCM

DXCM Rankings

DXCM Latest News

DXCM Latest SEC Filings

DXCM Stock Data

27.18B
388.32M
0.42%
97.51%
2.83%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN DIEGO